Advertisement

Picture [iito] Back into Ad 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5621 | Ordered by Date (descending)
1 2 3 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Anergis–Virometix: allergy immunotherapy, 202007– collab research study at HZI using SVLPs supported by TRANSVAC2 grant in house dust mite allergy 2020-07-09
CirQuest Labs–MLM Medical Labs: investment, 202007 acquisition of CirQuest Labs by MLM Medical Labs 2020-07-08
Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications 2020-07-08
Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties 2020-07-08
Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund 2020-07-03
CRISPR Therapeutics–SEVERAL: investment, 202006– public offering $450m+67.5m with 6.43m+964.3k common shares at $70/share 2020-06-29
Cutiss–Gisev Family Office: investment, 202006 financing round Series B totalling CHF20m incl lead investor Gisev Familiy Office 2020-06-29
Cutiss–SEVERAL: investment, 202006 financing round Series B CHF20m led by Gisev Familiy Office 2020-06-29
RareCyte–Scienion: single-cell dispenser, 202006 supply existent of cellenONE to RareCyte for CTC analysis technology by Cellenion 2020-06-22
Kaia Health–SEVERAL: investment, 202006 financing round Series B $26m bringing total funds raised to $50m 2020-06-18
Univ Bochum–Max Planck: antibiotics research, 202006– collab establishment CESAR Center for Antibiotics Research at Univ Bochum with LDC 2020-06-18
Univ Bochum–North Rhine-Westphalia (govt): grant, 202006– grant €4m from NRW + EFRO for establishment CESAR Center for Antibiotics Research with LDC 2020-06-18
DiogenX–Boehringer: investment, 202006 seed financing round totalling €4.5m incl investor BIVF 2020-06-16
DiogenX–SEVERAL: investment, 202006 seed financing round €4.5m from Advent France Biotechnology + BIVF + JDRF T1D Fund 2020-06-16
eTheRNA–Boehringer: investment, 202006 financing round Series B totalling €34m incl existing investor BIVF 2020-06-16
eTheRNA–SEVERAL: investment, 202006 financing round Series B €34m from all existing + new investors 2020-06-16
Qurient–Max Planck: proteasome inhibitors, 2012006– collab develop + license + founding of joint venture QLi5 Therapeutics GmbH 2020-06-16
CureVac–Germany (govt): investment, 202006 investment €300m direct equity investment by KfW 2020-06-15
Bit Bio–BY Capital: investment, 202006 financing round Series A totalling $41.5m incl co-investor BlueYard Capital 2020-06-13
Bit Bio–Mission Group: public relations, 202006 service existent by April Six 2020-06-13
Bit Bio–SEVERAL: investment, 202006 financing round Series A $41.5m led by Rick Klaunser + Bob Nelsen + Jim Tananbaum 2020-06-13
Lexent Bio–Roche: investment, 202006 acquisition of Lexent Bio by Foundation Medicine 2020-06-12
10x Genomics–Merck (DE): CRISPR technology, 202006 collab launch integrated solution for CRISPR research 2020-06-10
Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Belfius Insurance 2020-06-10
Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor FPIM 2020-06-10
Bioqube Ventures–EU (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor EIF 2020-06-10
Bioqube Ventures–Flanders (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor PMV 2020-06-10
Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab 2020-06-10
Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor JnJ Innovation 2020-06-10
Bioqube Ventures–Molenwater Groep: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Molenwater Groep 2020-06-10
Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al 2020-06-10
Royalty Pharma–AiCuris: letermovir, 202006 acquisition of partial royalty interest on letermovir for one-time payment of $220m by Royalty Pharma 2020-06-09
BRAIN–SEVERAL: investment, 202006 private placenment €14.94m with 1.8m new shares at €8.3/share 2020-06-03
AdvanceCor–Bavaria (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor Bayern Kapital 2020-06-02
AdvanceCor–First Capital Partner: investment, 202006 financing round totalling €3.9m incl co-investor First Capital Partner 2020-06-02
AdvanceCor–Germany (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor KfW Bank 2020-06-02
AdvanceCor–MIG Fonds: investment, 202006 financing round totalling €3.9m incl existing + lead investor MIG AG 2020-06-02
AdvanceCor–Occident Group: investment, 202006 financing round totalling €3.9m incl existing + co-investor Occident 2020-06-02
AdvanceCor–SEVERAL: investment, 202006 financing round €3.9m led by MIG AG 2020-06-02
Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility 2020-05-27
KI-SIGS project–Germany (govt): grant, 202005– funding €10m from German federal government 2020-05-27
Kumovis–Ffilipa Venture Capital: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor Ffilipa Venture Capital 2020-05-27
Kumovis–High-Tech Gründerfonds: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor HTGF 2020-05-27
Kumovis–Renolit: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Renolit SE 2020-05-27
Kumovis–SEVERAL: investment, 202005 financing round Series A €3.6m led by Renolit + Solvay Ventures 2020-05-27
Kumovis–Solvay: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Solvay Ventures 2020-05-27
Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital 2020-05-26
Spindiag–Baden-Württemberg (govt): grant, 202004 grant €6m for Spindiag + HSI-IMIT from Ministry of Economic Affairs 2020-05-26
Spindiag–SEVERAL: investment, 202005 financing round Series B €16.3m with investors WBG Pflegeheime + Think-Health Ventures et al. 2020-05-26
Spindiag–Think.Health Ventures: investment, 202005 financing round Series B totalling €16.3m incl new investor Think.Health Ventures 2020-05-26
Spindiag–WBG Pflegeheime: investment, 202005 financing round Series B totalling €16.3m incl existing investor WBG Pflegeheime 2020-05-26
Sterna Biologicals–MC Services: public relations, 202005 service existent by MC Services 2020-05-26
Sterna Biologicals–SEVERAL: investment, 202005 private placement €12m with existing + new investors 2020-05-26
Themis Bioscience–Merck (US): investment, 202005– acquisition €na all remaing shares of Themis via Merck subsidiary 2020-05-26
Poxel–Trophic Communications: public relations, 202005 service existent IR+ media EU/US by Trophic Communications 2020-05-25
Stratos–Roche: investment, 202005 acquisition €na of Stratos Genomics by Roche 2020-05-22
Idorsia–SEVERAL: investment, 202005 capital increase CHF330m offering of 11m new shares at CHF30/share to qualified investors 2020-05-19
Rentschler–Horizon Discovery: cell line development, 202005– license to CHOSource platform for cell line developm for difficult-to-express proteins 2020-05-19
Rentschler–MC Services: public relations, 202005 service existent by MC Services 2020-05-19
Apeiron–Austria (govt): grant, 202005– grant funding + guarantees €5.6m from FFG + WAW + AWS + Erste Bank 2020-05-18
Apeiron–SEVERAL: investment, 202005–202006 private placement €11.9m led by Vienna Insurance Group plus existing + new investors 2020-05-18
Apeiron–Vienna Insurance Group: investment, 202005–202006 private placement totalling €11.9m incl €7m from new + lead investor VIG 2020-05-18
Enzymicals–Syngulon: enzyme production technology, 202005– license non-excl to antibiotic-free selection technology of Syngulon 2020-05-16
OTHER–Enzymicals: enzymes, 202005 service production + supply of diagnostic enzymes using antibiotic-free production for undisclosed world leader 2020-05-16
Oribiotech–CellGenix: reagents, 202005– collab supply of GMP raw materials for closed-system CGT manufacturing system of Ori 2020-05-13
Polyganics–EU (govt): grant, 202005 EFRO grant €1.2m for clinical development of Liver + Pancreas Sealant Patch 2020-05-13
Bluebird Bio–Hitachi: contract manufacturing, 202005– supply expansion long-term developm + manufacturing by HCATS + Apceth for gene therapies 2020-05-11
Novartis–Dyno Therapeutics: gene therapy, 202005– collab design of AVV vectors for ophthalmic gene therapies using AI-based CapsidMap platform 2020-05-11
Pluristem–Dentons: legal services, 202005 supply service Dentons is adivsor with regard to €50m EIB loan financing 2020-05-05
ADC Therapeutics–Deerfield: credit, 202005– convertible credit facility $115m in two conditionable disbursements of $65m + $50m 2020-05-01
Moderna–Lonza: biologicals contract manufacturing, 202005–203004 collab strategic 10y manufacture of mRNA1273 vaccine + other Moderna products 2020-05-01
Pfizer–Valneva: Lyme disese vaccine, 202004– collab developm of VLA15 + commerc by Pfizer $130m upfront + $178m milestones + 2-digit tiered royalties 2020-04-30
Kurma–EU (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor EIF 2020-04-29
Kurma–Institut Pasteur: investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor Pasteur Institute 2020-04-29
Kurma–North Rhine-Westphalia (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor NRW.BANK 2020-04-29
Kurma–SEVERAL: investment, 202004 final closing of Kurma Biofund III with €160m 2020-04-29
Genedata–Cergentis: genomic software tools, –202004 collab developm of Genedata Selector s/w for automating TLA data analysis workflow 2020-04-28
Gustave Roussy–Biognosys: MS-based proteomics, 202004– collab using proteomic profiling in attempt to repurpose tocilizumab for Covid-19 2020-04-28
Compass Pathways–ATAI Life Sciences: investment, 202004 financing round Series B totalling $80m incl existing investor ATAI Life Sciences 2020-04-27
Compass Pathways–SEVERAL: investment, 202004 financing round Series B $80m from existing + new investors 2020-04-27
Heidelberg Pharma–Hopp Group: investment, 202004 private placement totalling €14.4m incl €13.7m from main investor Dievini Hopp 2020-04-27
Heidelberg Pharma–OTHER: investment, 202004 private placement totalling €14.4m incl €719k to institutional investors 2020-04-27
Heidelberg Pharma–SEVERAL: investment, 202004 private placement €14.4m with 2.82m new shares at €5.1/share incl €13.7m from Dievini Hopp 2020-04-27
ADC Therapeutics–SEVERAL: investment, 202004– IPO at NYSE filed 2nd time with SEC 2020-04-24
Pluristem–EU (govt): credit, 202004– EIB financing up to €50m in three milestone-dependent tranches 2020-04-24
FoRx Therapeutics–Life Sciences Partners: investment, 202004 seed financing round totalling €10m incl co-investor LSP 2020-04-22
FoRx Therapeutics–Merck (DE): investment, 202004 seed financing round totalling €10m incl co-lead investor M Ventures 2020-04-22
FoRx Therapeutics–Novartis: investment, 202004 seed financing round totalling €10m incl co-lead investor Novartis Venture Fund 2020-04-22
FoRx Therapeutics–Omega Funds: investment, 202004 seed financing round totalling €10m incl co-lead investor Omega Funds 2020-04-22
FoRx Therapeutics–Optimum Strategic Communications: public relations, 202004 service existent by Optimum 2020-04-22
FoRx Therapeutics–Pfizer: investment, 202004 seed financing round totalling €10m incl co-investor Pfizer Ventures 2020-04-22
FoRx Therapeutics–SEVERAL: investment, 202004 seed financing round €10m co-led by M Ventures + Novartis Venture Fund + Omega Funds 2020-04-22
Valneva–Dynavax: SARS-CoV-2 vaccine, 202004– collab development combining Valneva’s vaccine technology with adjuvant CpG 1018 of Dynavax 2020-04-22
Centogene–Ubirch: blockchain technology, 202004 collab announcing secure blockchain solution for storing SARS-CoV-2 test results 2020-04-17
Evotec–Leon-Nanodrugs: nanoparticle technology, 202004– collab €na strategic partnership incl equity investment 2020-04-16
Evox Therapeutics–Cevec: cell line technology, 202004– license €na for use of CAP technology to produce exosome therapeutics as part of ongoing collab 2020-04-16
Leon-Nanodrugs–Albany Private Equity: investment, 202004 financing round Series B incl existing + co-investor Albany Private Equity Holidngs Pty Ltd 2020-04-16
Leon-Nanodrugs–Bavaria (govt): investment, 202004 financing round Series B incl new + co-investor BayBG 2020-04-16
Leon-Nanodrugs–CD-Venture: investment, 202004 financing round Series B incl existing + co-investor CD-Venture GmbH 2020-04-16
Leon-Nanodrugs–Eckenstein-Geigy-Stiftung: investment, 202004 financing round Series B incl existing + co-investor Eckenstein-Geigy-Stiftung 2020-04-16
1 2 3 ... 55 56 57  next pagenext page



Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] No Content Marketing 650x80px

» top